/
As used in this report, the terms Aptose, Aptose Biosciences, the Company, "the "Corporation," we, us, our and similar references refer to Aptose Biosciences Inc. (formerly known as Lorus Therapeutics Inc.) and our consolidated subsidiaries, and the term Common Shares refers to our common shares, no par value. Aptose had historically qualified as a foreign private issuer for purposes of reporti…
Negative free cash flow of -$22M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$0.00
Net Income (TTM)
-$28M
▼ -0.1% YoY
Op. Margin
—
ROIC
—
Cash Flow & Balance Sheet
FCF (TTM)
-$25M
▲ +38.9% YoY
Op. Cash Flow (TTM)
-$25M
▲ +38.9% YoY
Net Debt
-$940K
Net Cash Position
Cash & Equiv.
$1M
Continue Research